Goldman Sachs Group set a CHF 325 price objective on Roche (VTX:ROG) in a report published on Wednesday morning. The firm currently has a buy rating on the healthcare company’s stock.

ROG has been the topic of several other reports. Deutsche Bank set a CHF 255 price objective on Roche and gave the stock a neutral rating in a report on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on Roche and gave the stock a neutral rating in a report on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a buy rating on shares of Roche in a report on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on Roche and gave the stock a neutral rating in a report on Friday, October 6th. Finally, Jefferies Group set a CHF 295 target price on Roche and gave the company a buy rating in a research report on Monday, October 16th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. Roche currently has a consensus rating of Hold and a consensus target price of CHF 261.84.

Shares of Roche (VTX ROG) remained flat at $CHF 241.70 during trading on Wednesday. The company had a trading volume of 1,440,000 shares, compared to its average volume of 1,670,000. Roche has a 52-week low of CHF 223.70 and a 52-week high of CHF 273.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/14/roche-rog-given-a-chf-325-price-target-at-goldman-sachs-group.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.